Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effect of parthenolide, an NLRP3 inflammasome inhibitor, on insulin resistance in high-fat diet-obese mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Canadian Science Publishing Country of Publication: Canada NLM ID: 0372712 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1205-7541 (Electronic) Linking ISSN: 00084212 NLM ISO Abbreviation: Can J Physiol Pharmacol Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2011- : Ottawa, ON : Canadian Science Publishing
      Original Publication: Ottawa, National Research Council of Canada.
    • الموضوع:
    • نبذة مختصرة :
      The activation of Nod-like receptor proteins (NLRP3) containing the pyrin domain inflammasome is a hallmark of the pathogenesis of metabolic disorders. Inhibition of the NLRP3 inflammasome by phytoconstituents has been attempted as a strategy to mitigate these disorders. Therefore, the present study aimed to evaluate the efficacy of an NLRP3 inflammasome inhibitor, parthenolide (PN; 5 mg/kg i.p.) against inflammation and insulin resistance in high-fat diet (HFD) - obese mice. Treatment with PN and pioglitazone (PIO; 30 mg/kg p.o.) attenuated lipopolysaccharide (LPS; 1 ng/ml) - induced elevation of tumor necrosis factor-α and interleukin-1β in mouse peritoneal macrophages in a dose-dependent manner. Sixty days of PN and PIO treatment marginally reduced obesity-induced insulin resistance in HFD-obese mice. PN treatment also decreased blood glucose from 14th to 60th day, supporting the hypothesis of simultaneous attenuation of inflammation and insulin resistance in obese mice. Thus, PN treatment was also evident with significant improvement in glucose tolerance and peripheral insulin resistance validated through the respective tolerance tests. Therefore, the present study suggests that PN, an NLRP3 inflammasome inhibitor, could be a possible therapeutic agent for attenuating obesity-induced insulin resistance.
    • Contributed Indexing:
      Keywords: cytokines; glucose intolerance; inflammasome; insulin resistance; intolérance au glucose; nod-like receptor proteins; pioglitazone; résistance à l’insuline
    • الرقم المعرف:
      0 (Blood Glucose)
      0 (Interleukin-1beta)
      0 (NLR Family, Pyrin Domain-Containing 3 Protein)
      0 (Nlrp3 protein, mouse)
      0 (Sesquiterpenes)
      0 (Tumor Necrosis Factor-alpha)
      2RDB26I5ZB (parthenolide)
      X4OV71U42S (Pioglitazone)
    • الموضوع:
      Date Created: 20220204 Date Completed: 20220304 Latest Revision: 20240226
    • الموضوع:
      20240226
    • الرقم المعرف:
      10.1139/cjpp-2021-0116
    • الرقم المعرف:
      35119950